Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma

12 Aug 2019

Abstract excerpt

Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Tumor Diagnosis and Treatments
Share to Histone Deacetylase Inhibitors Research
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31406254
DOI: 10.1038/s41388-019-0929-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaPMID 31406254Read ↗

IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells.Semantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaSemantic proximity Read ↗

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Semantic proximity Read ↗

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma CellsSemantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.Semantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?Semantic proximity Read ↗

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in ChondrosarcomaSemantic proximity Read ↗

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.Semantic proximity Read ↗

Prognostic impact of IDH mutations in chondrosarcoma.Semantic proximity Read ↗

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.Semantic proximity Read ↗

The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.